302 related articles for article (PubMed ID: 18463534)
1. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
Foster AE; Dotti G; Lu A; Khalil M; Brenner MK; Heslop HE; Rooney CM; Bollard CM
J Immunother; 2008 Jun; 31(5):500-5. PubMed ID: 18463534
[TBL] [Abstract][Full Text] [Related]
2. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
Bollard CM; Rössig C; Calonge MJ; Huls MH; Wagner HJ; Massague J; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 May; 99(9):3179-87. PubMed ID: 11964281
[TBL] [Abstract][Full Text] [Related]
3. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
Lacuesta K; Buza E; Hauser H; Granville L; Pule M; Corboy G; Finegold M; Weiss H; Chen SY; Brenner MK; Heslop HE; Rooney CM; Bollard CM
J Immunother; 2006; 29(3):250-60. PubMed ID: 16699368
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
Bollard CM; Tripic T; Cruz CR; Dotti G; Gottschalk S; Torrano V; Dakhova O; Carrum G; Ramos CA; Liu H; Wu MF; Marcogliese AN; Barese C; Zu Y; Lee DY; O'Connor O; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2018 Apr; 36(11):1128-1139. PubMed ID: 29315015
[TBL] [Abstract][Full Text] [Related]
6. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
7. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
[TBL] [Abstract][Full Text] [Related]
8. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
[TBL] [Abstract][Full Text] [Related]
9. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Hodgkin's disease.
Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
12. Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines.
Inman GJ; Allday MJ
J Gen Virol; 2000 Jun; 81(Pt 6):1567-78. PubMed ID: 10811940
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
[TBL] [Abstract][Full Text] [Related]
15. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
16. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
17. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
19. Dominant negative TGF-β receptor type II in T lymphocytes promotes anti-tumor immunity by modulating T cell subsets and enhancing CTL responses.
Li H; Guan Y; Han C; Zhang Y; Chen Y; Jiang L; Zhang P; Chen X; Wei W; Ma Y
Biomed Pharmacother; 2022 Apr; 148():112754. PubMed ID: 35228061
[TBL] [Abstract][Full Text] [Related]
20.
Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
